

Protocol

Transcranial Magnetic Stimulation as a Treatment of Depression and Other Psychiatric/Neurologic Disorders

(20150)

Medical Benefit		Effective Date: 01/01/16	Next Review Date: 09/18
Preauthorization	Yes	Review Dates: 05/09, 03/10, 03/11, 03/12, 03/13, 03/14, 07/14, 09/14, 09/15, 09/16, 09/17	

Preauthorization is required.

The following protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered services is subject to eligibility and the limitations noted in the patient's contract at the time the services are rendered.

Populations	Interventions	Comparators	Outcomes
Individuals: <ul style="list-style-type: none"> • With treatment-resistant depression 	Interventions of interest are: <ul style="list-style-type: none"> • Repetitive transcranial magnetic stimulation 	Comparators of interest are: <ul style="list-style-type: none"> • Pharmacotherapy • Psychological and behavioral therapy • Electroconvulsive therapy 	Relevant outcomes include: <ul style="list-style-type: none"> • Symptoms • Functional outcomes • Quality of life
Individuals: <ul style="list-style-type: none"> • With other psychiatric or neurologic disorders other than depression 	Interventions of interest are: <ul style="list-style-type: none"> • Repetitive transcranial magnetic stimulation 	Comparators of interest are: <ul style="list-style-type: none"> • Pharmacotherapy • Therapy as appropriate including either physical and occupational therapy or psychological and behavioral therapy 	Relevant outcomes include: <ul style="list-style-type: none"> • Symptoms • Functional outcomes • Quality of life

Description

Transcranial magnetic stimulation (TMS) is a noninvasive method of delivering electrical stimulation to the brain. TMS involves placement of a small coil over the scalp and passing a rapidly alternating current through the coil wire. The current produces a magnetic field that passes unimpeded through the scalp and bone, resulting in electrical stimulation that affects neuronal function. Repetitive transcranial magnetic stimulation (rTMS) is being evaluated for the treatment of treatment-resistant depression (TRD) and a variety of other psychiatric/neurologic disorders.

Summary of Evidence

For individuals who have TRD who receive rTMS, the evidence includes a large number of sham-controlled randomized controlled trials (RCTs) and meta-analyses of these trials. Relevant outcomes are symptoms, functional outcomes, and quality of life. The meta-analyses find a clinical benefit associated with rTMS for TRD with improved response rates and rates of remission compared with sham. The most recent meta-analyses have concluded that the effect of rTMS, on average depression scores, is smaller than the effect of electroconvulsive therapy (ECT) on TRD and that the mean improvement in depression scores with rTMS did not reach the minimal clinically important difference; however, clinically meaningful improvements were noted in a subgroup of

studies using higher frequency pulses. One potential area of benefit for rTMS is in accelerating or enhancing the response to antidepressant medications, and there is some evidence that rTMS, when given in conjunction with the initiation of pharmacologic therapy, improves the response rate compared with pharmacologic therapy alone. The effect of rTMS appears to be less robust when it is given in combination with a stable dose of antidepressant medication. Meta-analyses have also found that the efficacy of rTMS decreases with longer follow-up, though some studies have reported persistent response up to six months in some patients. There is limited evidence to compare the effects of these treatments on cognition, although the adverse events of rTMS appear to be minimal. While the most recent metaanalyses found that the effect of rTMS is smaller than the effect of ECT on TRD, because rTMS does not require general anesthesia or induce seizures, some individuals may decline ECT so the balance of incremental benefits and harms associated with rTMS may be a reasonable balance compared with ECT. Based on the short-term benefit observed in RCTs and the lack of alternative treatments, aside from ECT in patients with TRD, rTMS may be considered a treatment option in patients with TRD who meet specific criteria. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have psychiatric or neurologic disorders other than depression (e.g., amyotrophic lateral sclerosis, chronic pain, epilepsy, fibromyalgia, migraine headache, obsessive-compulsive disorder, panic disorder, Parkinson disease, posttraumatic stress disorder, schizophrenia, stroke, substance abuse and craving) who receive rTMS, the evidence includes numerous small RCTs and meta-analyses of these RCTs. Relevant outcomes are symptoms, functional outcomes, and quality of life. The trials included in the meta-analyses are typically small and of low methodologic quality. In addition, stimulation parameters have not been established, and trial results are heterogeneous. There are no large, high-quality trials for any of these conditions demonstrating efficacy. A demonstration of the durability of any treatment effects would also be needed. The evidence is insufficient to determine the effects of the technology on health outcomes.

Policy

Repetitive transcranial magnetic stimulation (rTMS) of the brain may be considered **medically necessary** as a treatment of major depressive disorder when all of the following conditions (1-3) have been met:

1. Confirmed diagnosis of severe major depressive disorder (single or recurrent) documented by standardized rating scales that reliably measure depressive symptoms; AND
2. Any one of the following (a, b, c, or d):
 - a. Failure of four trials of psychopharmacologic agents including two different agent classes and two augmentation trials; OR
 - b. Inability to tolerate a therapeutic dose of medications as evidenced by four trials of psychopharmacologic agents with distinct side effects; OR
 - c. History of response to rTMS in a previous depressive episode (at least three months since the prior episode); OR
 - d. Is a candidate for electroconvulsive therapy (ECT); further ECT would not be clinically superior to rTMS (e.g., in cases with psychosis, acute suicidal risk, catatonia or life-threatening inanition rTMS should NOT be utilized);

AND

3. Failure of a trial of a psychotherapy known to be effective in the treatment of major depressive disorder of an adequate frequency and duration, without significant improvement in depressive symptoms as documented by standardized rating scales that reliably measure depressive symptoms.

Repetitive TMS for major depressive disorder that does not meet the criteria listed above is considered **investigational**.

Continued treatment with rTMS of the brain as maintenance therapy is considered **investigational**.

Repetitive TMS of the brain is considered **investigational** as a treatment of all other psychiatric/neurologic disorders, including but not limited to bi-polar disorder, schizophrenia, obsessive-compulsive disorder, or migraine headaches.

Policy Guidelines

Repetitive transcranial magnetic stimulation should be performed using a U.S. Food and Drug Administration (FDA) cleared device in appropriately selected patients, by physicians who are adequately trained and experienced in the specific techniques used. A treatment course should not exceed five days a week for six weeks (total of 30 sessions), followed by a three-week taper of three TMS treatments in week one, two TMS treatments the next week, and one TMS treatment in the last week.

Contraindications to rTMS include:

- a. Seizure disorder or any history of seizure with increased risk of future seizure; OR
- b. Presence of acute or chronic psychotic symptoms or disorders (such as schizophrenia, schizophreniform or schizoaffective disorder) in the current depressive episode; OR
- c. Neurological conditions that include epilepsy, cerebrovascular disease, dementia, increased intracranial pressure, having a history of repetitive or severe head trauma, or with primary or secondary tumors in the central nervous system (CNS); OR
- d. Presence of an implanted magnetic-sensitive medical device located 30 centimeters or less from the TMS magnetic coil or other implanted metal items, including but not limited to a cochlear implant, implanted cardioverter defibrillator, pacemaker, vagus nerve stimulator, or metal aneurysm clips or coils, staples, or stents.

The following should be present for the administration of repetitive TMS:

- a. An attendant trained in basic cardiac life support and the management of complications such as seizures, as well as the use of the equipment must be present at all times; AND
- b. Adequate resuscitation equipment including, for example, suction and oxygen; AND
- c. The facility must maintain awareness of response times of emergency services (either fire/ambulance or "code team"), which should be available within five minutes. These relationships are reviewed on at least a one year basis and include mock drills.

Medicare Advantage

For Medicare Advantage transcranial magnetic stimulation (TMS) is considered **medically necessary** in adults who have a confirmed diagnosis of major depressive disorder (MDD), single or recurrent episode, and meet the following criteria (see Medicare Advantage Policy Guidelines):

- Resistance to treatment as evidenced by a lack of a clinically significant response to four (4) trials of psychopharmacologic agents in the current depressive episode;
 - Two different agent classes, at or above the minimum effective dose and duration and includes trials of at least two (2) evidence-based augmentation therapies; **or**
- Inability to tolerate psychopharmacologic agents as evidenced by four (4) trials of psychopharmacologic agents with distinct side effects; **or**
- History of response to TMS in a previous depressive episode; **or**
- History of response to electroconvulsive therapy (ECT) in a previous or current MDD episode, or inability to tolerate ECT, and TMS is considered a less invasive treatment option; **and**
- A trial of an evidence-based psychotherapy known to be effective in the treatment of MDD of an adequate frequency and duration without significant improvement in depressive symptoms as documented by standardized rating scales that reliably measure depressive symptoms; **and**
- The TMS treatment is delivered by a device that is FDA-approved or –cleared for the treatment of MDD in a safe and effective manner. TMS treatment should generally follow the protocol and parameters specified in the manufacturer’s user manual, with modifications only as supported by the published scientific evidence base; **and**
- The order for treatment (or retreatment) is written by a physician (MD or DO) who has examined the patient and reviewed the record. The physician must have experience in administering TMS therapy and the treatment must be given under direct supervision of this physician, i.e., he or she must be in the area and be immediately available.

TMS is considered **not medically necessary** for any of the following:

- Presence of psychotic symptoms in the current depressive episode;
- Acute or chronic psychotic disorder such as schizophrenia, schizophreniform disorder, or schizoaffective disorder;
- Neurologic conditions that include epilepsy, cerebrovascular disease, dementia, increased intracranial pressure, having a history of repetitive or severe head trauma, or with primary or secondary tumors in the central nervous system;
- Persons with conductive, ferromagnetic or other magnetic-sensitive metals implanted in their head which are non-removable and within 30 cm of the TMS magnetic coil. Examples include cochlear implants, implanted electrodes/stimulators, aneurysm clips or coils stents, and bullet fragments. (Dental amalgam fillings are not affected by the magnetic field and are acceptable for use with TMS.)
- Maintenance therapy; and
- All other conditions not included in the above list of “Indications.”

Retreatment may be considered **medically necessary** for patients who met the guidelines for initial treatment and subsequently developed relapse of depressive symptoms if the patient responded to prior treatments as evidenced by a greater than 50% improvement in standard rating scale measurements for depressive symptoms or if there were a relapse after remission [e.g., (GDS), PHQ-9, BDI, HAM-D, MADRS, QIDS or IDS-SR score].

Medicare Advantage Policy Guidelines

Limitations

The benefits of TMS use must be carefully considered against the risk of potential side effect in patients with any of the following:

- Seizure disorder or any history of seizure (except those induced by ECT or isolated febrile seizures in infancy or childhood without subsequent treatment or recurrence). Additional consideration should be given for individuals on medications which may lower the seizure threshold or with conditions rendering the patient more prone to seizures, such as alcoholism;
- Presence of vagus nerve stimulators leads in the carotid sheath;
- Presence of an implanted medical device located less than 30 cm from the TMS magnetic coil, including but not limited to pacemakers, implanted defibrillators, vagus nerve stimulators.

The attending physician must monitor and document the patient's clinical progress during treatment. The attending physician must use evidence-based validated depression monitoring scales such as the Geriatric Depression Scale (GDS), the Personal Health Questionnaire Depression Scale (PHQ-9), the Beck Depression Scale (BDI) Hamilton Rating Scale for Depression (HAM-D), the Montgomery Asberg Depression Rating Scale (MADRS), the Quick Inventory of Depressive Symptomatology (QIDS) or the Inventory for Depressive Symptomatology Systems Review (IDS-SR) to monitor treatment response and the achievement of remission of symptoms.

Background

Transcranial Magnetic Stimulation

TMS was first introduced in 1985 as a new method of noninvasive stimulation of the brain. The technique involves placement of a small coil over the scalp; passing a rapidly alternating current through the coil wire, which produces a magnetic field that passes unimpeded through the scalp and bone, resulting in electrical stimulation of the cortex. TMS was initially used to investigate nerve conduction; for example, TMS over the motor cortex will produce a contralateral muscular-evoked potential. The motor threshold, which is the minimum intensity of stimulation required to induce a motor response, is empirically determined for each person by localizing the site on the scalp for optimal stimulation of a hand muscle, then gradually increasing the intensity of stimulation. The stimulation site for treatment of depression is usually five cm anterior to the motor stimulation site.

Interest in the use of TMS as a treatment for depression was augmented by the development of a device that could deliver rapid, repetitive stimulation. Imaging studies had shown a decrease in activity of the left dorso-lateral prefrontal cortex (DLPFC) in depressed patients, and early studies suggested that high-frequency (e.g., five to 10 Hz) TMS of the left DLPFC had antidepressant effects. Low-frequency (one to two Hz) stimulation of the right DLPFC has also been investigated. The rationale for low-frequency TMS is inhibition of right frontal cortical activity to correct the interhemispheric imbalance. A combination approach (bilateral stimulation), or deep stimulation with an H1 coil, are also being explored. In contrast to electroconvulsive therapy, TMS does not require anesthesia and does not induce a convulsion.

Repetitive TMS

Repetitive TMS is also being tested as a treatment for a variety of other disorders including alcohol dependence, Alzheimer disease, neuropathic pain, obsessive-compulsive disorder, postpartum depression, Parkinson disease, stroke, posttraumatic stress disorder, panic disorder, epilepsy, dysphagia, Tourette syndrome, schizophrenia, migraine, spinal cord injury, fibromyalgia, and tinnitus. (See the Treatment of Tinnitus Protocol on rTMS for

tinnitus.) In addition to the potential for altering interhemispheric imbalance, it has been proposed that high-frequency rTMS may facilitate neuroplasticity.

Regulatory Status

Devices for transcranial stimulation have been cleared for marketing by the U.S. Food and Drug Administration (FDA) for diagnostic uses. The NeoPulse, now known as NeuroStar® TMS, was granted a de novo 510(k) classification by FDA in 2008. A number of devices subsequently received FDA clearance for the treatment of major depressive disorders in adults who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. Some devices are listed in Table 1. FDA product code: OBP.

Table 1. rTMS Devices Cleared by FDA for the Treatment of Major Depressive Disorder

Device	Manufacturer	FDA Clearance No.	FDA Clearance Date
NeuroStar® TMS	Neuronetics	DEN070003	2008
Brainsway™ H-Coil Deep TMS	Brainsway	K122288	2013
Rapid ² Therapy System	Magstim	K162935	2015
MagVita TMS Therapy System	Tonica Elektronik	K150641	2015
Neurosoft TMS	TeleEMG	K160309	2016

FDA: Food and Drug Administration; rTMS: repetitive transcranial magnetic stimulation

In 2013, the Cerena™ TMS device (eNeura Therapeutics) was granted a de novo 510(k) classification by FDA for the acute treatment of pain associated with migraine headache with aura. Warnings, precautions, and contraindications include the following:

- The device is only intended for use by patients experiencing the onset of pain associated with a migraine headache with aura.
- The device should not be used:
 - on headaches due to underlying pathology or trauma.
 - for medication overuse headaches.
- The device has not been demonstrated as safe and/or effective:
 - when treating cluster headache or chronic migraine headache.
 - when treating during the aura phase.
 - in relieving the associated symptoms of migraine (photophobia, phonophobia, and nausea).
 - in pregnant women, children under the age of 18, and adults over the age of 65.

The de novo 510(k) review process allows novel products with moderate or low-risk profiles and without predicates which would ordinarily require premarket approval as a class III device to be down-classified in an expedited manner and brought to market with a special control as a class II device.

In 2014, eNeura Therapeutics received 510(k) marketing clearance for the SpringTMS® for the treatment of migraine headache. The device differs from the predicate Cerena™ TMS device with the addition of an LCD screen, a use authorization feature, lithium battery pack, and smaller size. The stimulation parameters are unchanged. The sTMS Mini (eNeura Therapeutics) received marketing clearance by the FDA in 2016. FDA product code: OKP.

Related Protocols

Treatment of Tinnitus

Vagus Nerve Stimulation

Services that are the subject of a clinical trial do not meet our Technology Assessment Protocol criteria and are considered investigational. *For explanation of experimental and investigational, please refer to the Technology Assessment Protocol.*

It is expected that only appropriate and medically necessary services will be rendered. We reserve the right to conduct prepayment and postpayment reviews to assess the medical appropriateness of the above-referenced procedures. **Some of this protocol may not pertain to the patients you provide care to, as it may relate to products that are not available in your geographic area.**

References

We are not responsible for the continuing viability of web site addresses that may be listed in any references below.

1. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Transcranial magnetic stimulation for depression. TEC Assessments. 2009; Volume 24: Tab 5.
2. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Transcranial magnetic stimulation for depression. TEC Assessments. 2011; Volume 26: Tab 3.
3. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Transcranial magnetic stimulation for depression. TEC Assessments. 2013; Volume 28: Tab 9.
4. Gross M, Nakamura L, Pascual-Leone A, et al. Has repetitive transcranial magnetic stimulation (rTMS) treatment for depression improved? A systematic review and meta-analysis comparing the recent vs. the earlier rTMS studies. *Acta Psychiatr Scand.* Sep 2007; 116(3):165-173. PMID 17655557
5. Schutter DJ. Antidepressant efficacy of high-frequency transcranial magnetic stimulation over the left dorso-lateral prefrontal cortex in double-blind sham-controlled designs: a meta-analysis. *Psychol Med.* Jan 2009; 39(1):65-75. PMID 18447962
6. Gaynes B, Lux L, Lloyd S, et al. Nonpharmacologic Interventions for Treatment-Resistant Depression in Adults. Comparative Effectiveness Review No. 33 (AHRQ Publication No. 11-EHC056-EF). Rockville, MD: Agency for Healthcare Research and Quality; 2011.
7. Berlim MT, Van den Eynde F, Daskalakis ZJ. High-frequency repetitive transcranial magnetic stimulation accelerates and enhances the clinical response to antidepressants in major depression: a meta-analysis of randomized, double-blind, and sham-controlled trials. *J Clin Psychiatry.* Feb 2013; 74(2):e122-129. PMID 23473357
8. Berlim MT, Van den Eynde F, Daskalakis ZJ. Efficacy and acceptability of high frequency repetitive transcranial magnetic stimulation (rTMS) versus electroconvulsive therapy (ECT) for major depression: a systematic review and meta-analysis of randomized trials. *Depress Anxiety.* Jul 2013; 30(7):614-623. PMID 23349112
9. Health Quality Ontario. Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis of randomized controlled trials. *Ont Health Technol Assess Ser.* 2016; 16(5):1-66. PMID 27099642

10. O'Reardon JP, Solvason HB, Janicak PG, et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. *Biol Psychiatry*. Dec 1 2007; 62(11):1208-1216. PMID 17573044
11. Food and Drug Administration. 510(k) Summary: Brainsway deep TMS System. 2013; http://www.accessdata.fda.gov/cdrh_docs/pdf12/k122288.pdf. Accessed May 19, 2017.
12. Kedzior KK, Reitz SK, Azorina V, et al. Durability OF the antidepressant effect of the high-frequency repetitive transcranial magnetic stimulation (rTMS) In the absence of maintenance treatment in major depression: a systematic review and meta-analysis of 16 double-blind, randomized, sham-controlled trials. *Depress Anxiety*. Mar 2015; 32(3):193-203. PMID 25683231
13. Dunner DL, Aaronson ST, Sackeim HA, et al. A multisite, naturalistic, observational study of transcranial magnetic stimulation for patients with pharmacoresistant major depressive disorder: durability of benefit over a 1-year follow-up period. *J Clin Psychiatry*. Dec 2014; 75(12):1394-1401. PMID 25271871
14. Richieri R, Guedj E, Michel P, et al. Maintenance transcranial magnetic stimulation reduces depression relapse: a propensity-adjusted analysis. *J Affect Disord*. Oct 2013; 151(1):129-135. PMID 23790811
15. Connolly KR, Helmer A, Cristancho MA, et al. Effectiveness of transcranial magnetic stimulation in clinical practice post-FDA approval in the United States: results observed with the first 100 consecutive cases of depression at an academic medical center. *J Clin Psychiatry*. Apr 2012; 73(4):e567-573. PMID 22579164
16. Janicak PG, Nahas Z, Lisanby SH, et al. Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study. *Brain Stimul*. Oct 2010; 3(4):187-199. PMID 20965447
17. Fang J, Zhou M, Yang M, et al. Repetitive transcranial magnetic stimulation for the treatment of amyotrophic lateral sclerosis or motor neuron disease. *Cochrane Database Syst Rev*. May 31, 2013; 5(5):CD008554. PMID 23728676
18. O'Connell NE, Wand BM, Marston L, et al. Non-invasive brain stimulation techniques for chronic pain. *Cochrane Database Syst Rev*. Apr 11 2014; 4(4):CD008208. PMID 24729198
19. Chen R, Spencer DC, Weston J, et al. Transcranial magnetic stimulation for the treatment of epilepsy. *Cochrane Database Syst Rev*. Aug 11 2016(8):CD011025. PMID 27513825
20. Sun W, Mao W, Meng X, et al. Low-frequency repetitive transcranial magnetic stimulation for the treatment of refractory partial epilepsy: a controlled clinical study. *Epilepsia*. Oct 2012; 53(10):1782-1789. PMID 22950513
21. Saltychev M, Laimi K. Effectiveness of repetitive transcranial magnetic stimulation in patients with fibromyalgia: a meta-analysis. *Int J Rehabil Res*. Mar 2017; 40(1):11-18. PMID 27977465
22. Food and Drug Administration. De Novo classification request for cerena transcranial magnetic stimulator (TMS) device. 2013; http://www.accessdata.fda.gov/cdrh_docs/reviews/K130556.pdf. Accessed May 19, 2017.
23. Berlim MT, Neufeld NH, Van den Eynde F. Repetitive transcranial magnetic stimulation (rTMS) for obsessive-compulsive disorder (OCD): an exploratory meta-analysis of randomized and sham-controlled trials. *J Psychiatr Res*. Aug 2013; 47(8):999-1006. PMID 23615189
24. Trevizol AP, Shiozawa P, Cook IA, et al. Transcranial magnetic stimulation for obsessive-compulsive disorder: an updated systematic review and meta-analysis. *J ECT*. Dec 2016; 32(4):262-266. PMID 27327557
25. Li H, Wang J, Li C, et al. Repetitive transcranial magnetic stimulation (rTMS) for panic disorder in adults. *Cochrane Database Syst Rev*. Sep 17 2014; 9(9):CD009083. PMID 25230088
26. Mantovani A, Aly M, Dagan Y, et al. Randomized sham controlled trial of repetitive transcranial magnetic stimulation to the dorsolateral prefrontal cortex for the treatment of panic disorder with comorbid major depression. *J Affect Disord*. Jan 10 2013; 144(1-2):153-159. PMID 22858212
27. Chou YH, Hickey PT, Sundman M, et al. Effects of repetitive transcranial magnetic stimulation on motor symptoms in Parkinson disease: a systematic review and meta-analysis. *JAMA Neurol*. Apr 2015; 72(4):432-440. PMID 25686212

28. Shirota Y, Ohtsu H, Hamada M, et al. Supplementary motor area stimulation for Parkinson disease: a randomized controlled study. *Neurology*. Apr 9 2013; 80(15):1400-1405. PMID 23516319
29. Trevizol AP, Barros MD, Silva PO, et al. Transcranial magnetic stimulation for posttraumatic stress disorder: an updated systematic review and meta-analysis. *Trends Psychiatry Psychother*. Jan-Mar 2016; 38(1):50-55. PMID 27074341
30. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Transcranial magnetic stimulation for the treatment of schizophrenia. *TEC Assessments*. 2011; Volume 26: Tab 6.
31. Dougall N, Maayan N, Soares-Weiser K, et al. Transcranial magnetic stimulation (TMS) for schizophrenia. *Cochrane Database Syst Rev*. Aug 20 2015; 8(8):CD006081. PMID 26289586
32. Hao Z, Wang D, Zeng Y, et al. Repetitive transcranial magnetic stimulation for improving function after stroke. *Cochrane Database Syst Rev*. May 31, 2013; 5(5):CD008862. PMID 23728683
33. Le Q, Qu Y, Tao Y, et al. Effects of repetitive transcranial magnetic stimulation on hand function recovery and excitability of the motor cortex after stroke: a meta-analysis. *Am J Phys Med Rehabil*. May 2014; 93(5):422-430. PMID 24429509
34. Li Y, Qu Y, Yuan M, et al. Low-frequency repetitive transcranial magnetic stimulation for patients with aphasia after stroke: A meta-analysis. *J Rehabil Med*. Sep 3 2015; 47(8):675-681. PMID 26181486
35. Graef P, Dadalt ML, Rodrigues DA, et al. Transcranial magnetic stimulation combined with upper-limb training for improving function after stroke: A systematic review and meta-analysis. *J Neurol Sci*. Oct 15 2016; 369:149-158. PMID 27653882
36. Jansen JM, Daams JG, Koeter MW, et al. Effects of non-invasive neurostimulation on craving: a meta-analysis. *Neurosci Biobehav Rev*. Dec 2013; 37(10 Pt 2):2472-2480. PMID 23916527
37. American Psychiatric Association. Practice Guidelines for the treatment of patients with major depressive disorder. 2010; http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf. Accessed May 19, 2017.
38. American Psychiatric Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder. 2007; http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/ocd.pdf. Accessed May 19, 2017.
39. Lefaucheur JP, Andre-Obadia N, Antal A, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). *Clin Neurophysiol*. Nov 2014; 125(11):2150-2206. PMID 25034472
40. Murphy TK, Lewin AB, Storch EA, et al. Practice parameter for the assessment and treatment of children and adolescents with tic disorders. *J Am Acad Child Adolesc Psychiatry*. Dec 2013; 52(12):1341-1359. PMID 24290467
41. National Institute for Health and Care Excellence (NICE). Repetitive transcranial magnetic stimulation for depression [IPG-542]. 2015; <https://www.nice.org.uk/guidance/ipg542>. Accessed May 19, 2017.
42. National Institute for Health and Care Excellence (NICE). Transcranial magnetic stimulation for treating and preventing migraine [IPG477]. 2014; <https://www.nice.org.uk/guidance/ipg477>. Accessed May 19, 2017.
43. Miyasaki JM, Shannon K, Voon V, et al. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*. Apr 11 2006; 66(7):996-1002. PMID 16606910
44. Kennedy SH, Milev R, Giacobbe P, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. IV. Neurostimulation therapies. *J Affect Disord*. Oct 2009; 117 Suppl 1:S44-53. PMID 19656575
45. Lam RW, Chan P, Wilkins-Ho M, et al. Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and metaanalysis. *Can J Psychiatry*. Sep 2008; 53(9):621-631. PMID 18801225
46. National Government Services, Inc. Local Coverage Determination (LCD): Transcranial Magnetic Stimulation (L33398) For services performed on or after 10/01/2015.